1. Home
  2. Analysis
  3. Rinvoq
  4. Daliresp

Rinvoq and Daliresp drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among 3 people who take Rinvoq and Daliresp. Common interactions include disability among females.

The phase IV clinical study analyzes what interactions people who take Rinvoq and Daliresp have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 26, 2023

3 people who take Rinvoq and Daliresp together, and have interactions are studied.

What is Rinvoq?

Rinvoq has active ingredients of upadacitinib. Currently, eHealthMe is studying from 36,447 Rinvoq users.

What is Daliresp?

Daliresp has active ingredients of roflumilast. It is used in chronic obstructive pulmonary disease. Currently, eHealthMe is studying from 4,477 Daliresp users.

Number of Rinvoq and Daliresp reports submitted per year:

Rinvoq and Daliresp drug interactions.

Common Rinvoq and Daliresp drug interactions by gender *:

female:

  1. Disability
  2. Fibrin d dimer increased
  3. Small intestinal obstruction
  4. Idiopathic pulmonary fibrosis
  5. Pulmonary fibrosis
  6. Gastrointestinal pain
  7. Heart rate increased
  8. Impaired work ability
  9. Lower limb fracture
  10. Pain

male:

n/a

Common Rinvoq and Daliresp drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Disability
  2. Fibrin d dimer increased
  3. Gastrointestinal pain
  4. Heart rate increased
  5. Impaired work ability
  6. Pain
  7. Pain in extremity
  8. Pancreatic enzymes increased
  9. Rheumatoid arthritis
  10. Small intestinal obstruction

* Approximation only. Some reports may have incomplete information.

Do you take Rinvoq and Daliresp?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drug side effects by duration, gender and age:

Common Rinvoq drug interactions:

Browse interactions between Rinvoq and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Daliresp drug interactions:

Browse interactions between Daliresp and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on upadacitinib and roflumilast (the active ingredients of Rinvoq and Daliresp, respectively), and Rinvoq and Daliresp (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Rinvoq and Daliresp.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.